Table 2.

Patient disease activity scores according to KIR and HLA-C genotype status

	Group I (2DS2+HLA-C homo)	Group IV (2DS2−HLA-C hetero)
DAS28 at baseline	6.05 (range, 4.28–8.96)	5.64 (range, 3.75–7.38)
DAS28 after 3 months	4.25 (range, 2.11–7.27)	5.16 (range, 1.95–7.22)
DAS28 improvement	1.80 (range, −1.85 to 3.92)	0.48 (range, −2.25 to 3.32)
# responders/non-responders	13/3	5/13
P-value of improvement	0.004	0.161

Group I: KIR2DS2 positive and HLA-C homozygous (C1/C1 or C2/C2), Group IV: KIR2DS2 negative and HLA-C heterozygous (C1/C2)